DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs

BACKGROUND: DUAL I China, one of the DUAL trials, assessed efficacy/safety of insulin degludec/liraglutide (IDegLira) in Chinese adults with type 2 diabetes (T2D) not controlled by oral antidiabetic drugs (OADs). METHODS: This phase 3a, treat‐to‐target multicenter trial randomized participants (glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Weiqing, Agner, Bue F. Ross, Luo, Bin, Liu, Lei, Liu, Ming, Peng, Yongde, Qu, Shen, Stachlewska, Karolina Amelia, Wang, Guixia, Yuan, Guoyue, Zhang, Qiu, Ning, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366571/
https://www.ncbi.nlm.nih.gov/pubmed/35762390
http://dx.doi.org/10.1111/1753-0407.13286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366571/
https://www.ncbi.nlm.nih.gov/pubmed/35762390
http://dx.doi.org/10.1111/1753-0407.13286

Ejemplares similares